Reduced Apolipoproteins C-I and C-III in Stomach Cancer Patients
Author Information
Author(s): Cohen Meital, Yossef Rami, Erez Tamir, Kugel Aleksandra, Welt Michael, Karpasas Mark M., Bones Jonathan, Rudd Pauline M., Taieb Julien, Boissin Herve, Harats Dror, Noy Karin, Tekoah Yoram, Lichtenstein Rachel G., Rubin Eitan, Porgador Angel
Primary Institution: Ben Gurion University of the Negev, Beer Sheva, Israel
Hypothesis
Can serum apolipoproteins C-I and C-III serve as biomarkers for stomach cancer?
Conclusion
Serum levels of apolipoproteins C-I and C-III are significantly lower in stomach cancer patients compared to cancer-free controls.
Supporting Evidence
- Nine signature peptides were identified that can distinguish stomach cancer patients from cancer-free controls.
- Prediction accuracy of 88.4% was achieved using a combination of serum levels of apoC-I, apoC-III, CA19-9, and CRP.
- Three of the identified peptides corresponded to apolipoproteins C-I and C-III.
Takeaway
Doctors found that two proteins in the blood can help tell if someone has stomach cancer.
Methodology
The study analyzed serum samples using mass spectrometry and immunoassays to identify peptide signatures for stomach cancer.
Potential Biases
Potential bias from sample handling and processing differences between the two biorepositories.
Limitations
The study's findings may be influenced by source-related biases due to different biorepositories.
Participant Demographics
The study included 103 individuals, with a mix of stomach cancer patients and cancer-free controls, including some gastritis patients.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website